ClinicalTrials.gg
CompletedNCT01716806Updated Jun 11, 2024Results posted

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

A Phase 2 interventional study of brentuximab vedotin and bendamustine in Hodgkin Disease and Peripheral T Cell Lymphoma, sponsored by Seagen Inc.. Completed at 54 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-11.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
131
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.

Enrollment
15th of 80
131 · median 52
Started
2012
with 6 others
Phase 2
41 of 80
8 open now
Registered
17th of 80
by date
Lead sponsor
12 of 80
Seagen Inc.

Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 15th largest by enrollment, is one of 7 that started in 2012, is one of 41 in phase 2, and was the 17th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing Brentuximab Vedotin in Hodgkin Disease, or all of them as a file.
02

Study summary

This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them unable to have standard chemotherapy treatment. The study will look at brentuximab vedotin alone and combined with other drugs.

Read the detailed description

This study is designed to evaluate the efficacy and tolerability of brentuximab vedotin as monotherapy and in combination with other agents as frontline therapy. There are 6 parts of the study. The population to be studied includes treatment-naïve patients with classical Hodgkin lymphoma (HL) or treatment-naïve patients with CD30-expressing peripheral T-cell lymphoma (PTCL).

03

Conditions studied

  • Hodgkin Disease
  • Peripheral T Cell Lymphoma

Keywords

  • Antibody-Drug Conjugate
  • Antibodies, Monoclonal
  • Hematologic Diseases
  • Hodgkin Disease
  • Antigens, CD30
  • Lymphoma
  • monomethylauristatin E
  • Drug Therapy
  • CD30-expression
  • PTCL
  • Seattle Genetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parts A, B, C, and D: 60 years of age or older
  • Treatment-naive patients with histopathological diagnosis of classical Hodgkin lymphoma (Parts A, B, C, D, and E)
  • Treatment-naive patients with CD30-expressing PTCL (Part F)
  • Ineligible for or have declined initial conventional combination chemotherapy for HL (Parts A, B, C, and D)
  • Unsuitable or unfit for initial conventional combination chemotherapy for HL (Part E) or CD30-expressing PTCL due to the presence of comorbidity-factors, as documented by:

    • A CIRS score of 10 or greater
    • Requiring assistance with or dependence on other for any instrumental activities of daily living (IADLs)
  • of at least 1.5 cm as documented by radiographic technique
  • (ECOG) performance status less than or equal to 3 (Parts, A, B, C, E, and F) or less than or equal to 2 (Part D)

Exclusion criteria

Exclusion Criteria:

  • Symptomatic neurologic disease compromising IADLs or requiring medication
  • History of progressive multifocal leukoencephalopathy
  • Grade 3 or higher viral, bacterial, or fungal infection within 2 weeks prior to the first dose of brentuximab vedotin
  • Concurrent use of other agents
  • Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not completed 4 weeks prior to first dose of study drug
  • History of another within 1 year before first dose of study drug (Parts E and F only)
  • Part D only:

    • Received any prior immune-oncology therapy
    • History of known or suspected disease
    • Prior stem cell transplant
    • History of cerebral vascular event within 6 months of first dose of study drug
    • Active interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicology
    • Known history of pancreatitis
  • Parts D, E, and F only:

    • Known cerebral/meningeal disease related to the underlying malignancy
    • Systemic treatment with or other medications within 1 week of enrollment
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    Part A: Brentuximab Vedotin in HL Patients

    Drug: brentuximab vedotin

  • Experimental
    Part B: Brentuximab Vedotin + Dacarbazine in HL Patients

    Drug: brentuximab vedotin · Drug: dacarbazine

  • Experimental
    Part C: Brentuximab Vedotin + Bendamustine in HL Patients

    Drug: brentuximab vedotin · Drug: bendamustine

  • Experimental
    Part D: Brentuximab Vedotin + Nivolumab in HL Patients

    Drug: brentuximab vedotin · Drug: nivolumab

  • Experimental
    Part E: Brentuximab Vedotin in HL Patients

    Drug: brentuximab vedotin

  • Experimental
    Part F: Brentuximab Vedotin in PTCL Patients

    Drug: brentuximab vedotin

Interventions

  • 1.8 mg/kg every 3 weeks by IV infusion

    Also known as: Adcetris; SGN-35

  • 70 mg/m\^2 by IV infusion on Days 1 and 2 of 3-week cycle

  • 375 mg/m\^2 every 3 weeks by IV infusion

  • 3 mg/kg every 3 weeks by IV infusion

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) According to the Revised Response Criteria for Malignant Lymphoma (Parts A, B, and C)

    Objective response rate (ORR) per investigator was defined as the percentage of subjects with complete response (CR) or partial response (PR) through the end of study or prior to the start of new anti-cancer treatment (including stem cell transplant, and excluding consolidative radiotherapy) other than the study treatment. For Parts A, B, and C the response was assessed using the Revised Response Criteria for Malignant Lymphoma (Cheson 2007).

    Time frame: Up to 81 months

  2. ORR According to the Lugano Classification Revised Staging System for Nodal Non-Hodgkin and Hodgkin Lymphomas (Lugano Criteria) and the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) (Part D)

    Objective response rate (ORR) per investigator was defined as the percentage of subjects with CR or PR through the end of study or prior to the start of new anti-cancer treatment (including stem cell transplant, and excluding consolidative radiotherapy) other than the study treatment. For Part D, the response was assessed using the Lugano Classification Revised Staging System for nodal non-Hodgkin and cHL (Lugano criteria) and the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC).

    Time frame: Up to 60 months

  3. ORR According to Modified Lugano Criteria Per Blinded Independent Central Review (BICR) (Parts E and F)

    Objective response rate (ORR) per investigator was defined as the percentage of subjects with CR or PR through the end of study or prior to the start of new anti-cancer treatment (including stem cell transplant, and excluding consolidative radiotherapy) other than the study treatment. For Parts E and F, the response was assessed per blinded independent central review (BICR) using the modified Lugano criteria.

    Time frame: Up to 31 months

Secondary outcomes

  1. Number of Participants With Adverse Events

    A treatment-emergent AE (TEAE) is defined as a newly occurring or worsening AE after the first dose of any study drug component. Treatment-related AEs are defined as treatment-emergent AEs that are determined by the investigator to be related to the treatment on study. TEAEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.03). The CTCAE displays Grades 1 through 5, where Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe or medically significant but not immediately life-threatening, Grade 4: Life-threatening consequences, Grade 5: Death related to AE.

    Time frame: Up to 122 months

  2. Number of Participants With Laboratory Abnormalities

    Laboratory values were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.03). The CTCAE displays Grades 1 through 5, where Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe or medically significant but not immediately life-threatening, Grade 4: Life-threatening consequences, Grade 5: Death related to AE.

    Time frame: Up to 30 months

  3. Complete Response Rate

    Complete response rate is defined as the percentage of patients with CR

    Time frame: Up to 81 months

  4. Duration of Complete Response

    Duration of CR per investigator was defined as the time from start of the first documentation of CR to the first documentation of tumor progression or to death due to any cause, whichever came first. For Parts E and F, the assessment was per BICR.

    Time frame: Up to 81 months

  5. Duration of Objective Response

    Duration of response per investigator was defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression (PD) based on radiographic evidence of progression or to death due to any cause, whichever came first. For Parts E and F, the assessment was per BICR.

    Time frame: Up to 81 months

  6. Progression-free Survival

    Progression-free survival (PFS) per investigator was defined as the time from start of study treatment to first documentation of tumor progression or to death due to any cause, whichever came first. For Parts E and F, the assessment was per BICR.

    Time frame: Up to 83 months

  7. Disease Control Rate

    Disease control rate (DCR) per investigator was defined as the percentage of subjects with CR, PR, or SD, per investigator assessment of best clinical response per Cheson 2007. For Parts E and F, the assessment was per BICR.

    Time frame: Up to 81 months

  8. ORR According to Lugano Criteria Per BICR (Parts E and F)

    Objective response rate (ORR) per investigator was defined as the percentage of subjects with CR or PR through the end of study or prior to the start of new anti-cancer treatment (including stem cell transplant, and excluding consolidative radiotherapy) other than the study treatment.

    Time frame: Up to 31 months

  9. B Symptom Resolution Rate

    B symptom resolution rate per investigator was defined as the percentage of subjects with lymphoma-related B symptoms at baseline who achieved resolution of all B symptoms at any time during the treatment period.

    Time frame: Up to 42 weeks

  10. Number of Participants With Brentuximab Vedotin Antitherapeutic Antibodies (ATA)

    Time frame: Up to 30 months

  11. Number of Participants With Nivolumab Antitherapeutic Antibodies (ATA) (Part D Only)

    Time frame: Up to 30 months

  12. Overall Survival (Parts E and F Only)

    Overall survival (OS) per investigator was defined as the time from date of enrollment to date of death due to any cause.

    Time frame: Up to 44 months

07

Results

Posted Jun 11, 2024

Participant flow

Participant flow — Overall Study
MilestonePart APart BPart CPart DPart EPart F
Started28222221317
Received at least one dose of study drug27222021307
Completed000000
Not completed28222221317
Withdrew: Patient withdrawal of consent424320
Withdrew: Lost to follow-up330210
Withdrew: Death139124105
Withdrew: Received treatment past data cutoff of up to 16 doses of bv. aes collected until end of study.000011
Withdrew: Pi decision000010
Withdrew: Change in performance status100000
Withdrew: Sponsor terminated enrollment into part c001000
Withdrew: Sponsor direction78512161

Outcome measures

PrimaryObjective Response Rate (ORR) According to the Revised Response Criteria for Malignant Lymphoma (Parts A, B, and C)

Objective response rate (ORR) per investigator was defined as the percentage of subjects with complete response (CR) or partial response (PR) through the end of study or prior to the start of new anti-cancer treatment (including stem cell transplant, and excluding consolidative radiotherapy) other than the study treatment. For Parts A, B, and C the response was assessed using the Revised Response Criteria for Malignant Lymphoma (Cheson 2007).

Time frame:
Up to 81 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) According to the Revised Response Criteria for Malignant Lymphoma (Parts A, B, and C)
Percentage of participantsPart APart BPart C
Objective Response Rate (ORR) According to the Revised Response Criteria for Malignant Lymphoma (Parts A, B, and C)93 (75.7 to 99.1)95 (77.2 to 99.9)85 (62.1 to 96.8)
PrimaryORR According to the Lugano Classification Revised Staging System for Nodal Non-Hodgkin and Hodgkin Lymphomas (Lugano Criteria) and the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) (Part D)

Objective response rate (ORR) per investigator was defined as the percentage of subjects with CR or PR through the end of study or prior to the start of new anti-cancer treatment (including stem cell transplant, and excluding consolidative radiotherapy) other than the study treatment. For Part D, the response was assessed using the Lugano Classification Revised Staging System for nodal non-Hodgkin and cHL (Lugano criteria) and the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC).

Time frame:
Up to 60 months
Reported as:
Number · Percentage of participants
ORR According to the Lugano Classification Revised Staging System for Nodal Non-Hodgkin and Hodgkin Lymphomas (Lugano Criteria) and the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) (Part D)
Percentage of participantsPart D
ORR According to the Lugano Classification Revised Staging System for Nodal Non-Hodgkin and Hodgkin Lymphomas (Lugano Criteria) and the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) (Part D)86 (63.7 to 97.0)
PrimaryORR According to Modified Lugano Criteria Per Blinded Independent Central Review (BICR) (Parts E and F)

Objective response rate (ORR) per investigator was defined as the percentage of subjects with CR or PR through the end of study or prior to the start of new anti-cancer treatment (including stem cell transplant, and excluding consolidative radiotherapy) other than the study treatment. For Parts E and F, the response was assessed per blinded independent central review (BICR) using the modified Lugano criteria.

Time frame:
Up to 31 months
Reported as:
Number · Percentage of participants
ORR According to Modified Lugano Criteria Per Blinded Independent Central Review (BICR) (Parts E and F)
Percentage of participantsPart EPart F
ORR According to Modified Lugano Criteria Per Blinded Independent Central Review (BICR) (Parts E and F)60 (40.6 to 77.3)43 (9.9 to 81.6)
SecondaryNumber of Participants With Adverse Events

A treatment-emergent AE (TEAE) is defined as a newly occurring or worsening AE after the first dose of any study drug component. Treatment-related AEs are defined as treatment-emergent AEs that are determined by the investigator to be related to the treatment on study. TEAEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.03). The CTCAE displays Grades 1 through 5, where Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe or medically significant but not immediately life-threatening, Grade 4: Life-threatening consequences, Grade 5: Death related to AE.

Time frame:
Up to 122 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsPart APart BPart CPart DPart EPart F
Any TEAE27222021307
Treatment-related TEAE25221918246
Any grade 3 or higher TEAE17101816187
Treatment-related grade 3 or higher TEAE139161284
Any treatment-emergent (TE) serious adverse event (SAE)54134144
Treatment-related TE SAE339031
TEAE leading to treatment discontinuation111112593
Treatment-related TEAE leading to treatment discontinuation1198252
TEAE leading to death003142
Treatment-related TEAE leading to death000011
SecondaryNumber of Participants With Laboratory Abnormalities

Laboratory values were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.03). The CTCAE displays Grades 1 through 5, where Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe or medically significant but not immediately life-threatening, Grade 4: Life-threatening consequences, Grade 5: Death related to AE.

Time frame:
Up to 30 months
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsPart APart BPart CPart DPart EPart F
Hemoglobin High, Grade 1210110
Hemoglobin High. Grade 2000000
Hemoglobin High. Grade 3000000
Hemoglobin High. Grade 4000000
Hemoglobin Low, Grade 1106109134
Hemoglobin Low, Grade 2566561
Hemoglobin Low, Grade 3101200
Hemoglobin Low, Grade 4000000
Leukocytes Low, Grade 1232354
Leukocytes Low, Grade 2335311
Leukocytes Low, Grade 3015110
Leukocytes Low, Grade 4001000
Lymphocytes High, Grade 1000000
Lymphocytes High, Grade 2000121
Lymphocytes High, Grade 3000000
Lymphocytes High, Grade 4000000
Lymphocytes Low, Grade 1000070
Lymphocytes Low, Grade 2472672
Lymphocytes Low, Grade 3626212
Lymphocytes Low, Grade 4009100
Neutrophils Low, Grade 1000200
Neutrophils Low, Grade 2345221
Neutrophils Low, Grade 3213222
Neutrophils Low, Grade 4021110
Platelets Low, Grade 1428352
Platelets Low, Grade 2212100
Platelets Low, Grade 3000000
Platelets Low, Grade 4000100
Alanine Aminotransferase High, Grade 18961670
Alanine Aminotransferase High, Grade 2410000
Alanine Aminotransferase High, Grade 3100200
Alanine Aminotransferase High, Grade 4000000
Albumin Low, Grade 1869963
Albumin Low, Grade 2335640
Albumin Low, Grade 3010000
Albumin Low, Grade 4000000
Alkaline Phosphatase High, Grade 1101054123
Alkaline Phosphatase High, Grade 2302400
Alkaline Phosphatase High, Grade 3100100
Alkaline Phosphatase High, Grade 4000000
Amylase High, Grade 1000500
Amylase High, Grade 2000200
Amylase High, Grade 3000300
Amylase High, Grade 4000000
Aspartate Aminotransferase High, Grade 114881690
Aspartate Aminotransferase High, Grade 2111110
Aspartate Aminotransferase High, Grade 3200110
Aspartate Aminotransferase High, Grade 4000000
Calcium Corrected for Albumin High, Grade 1101261
Calcium Corrected for Albumin High, Grade 2100200
Calcium Corrected for Albumin High, Grade 3000000
Calcium Corrected for Albumin High, Grade 4000000
Calcium Corrected for Albumin Low, Grade 1301122
Calcium Corrected for Albumin Low, Grade 2001000
Calcium Corrected for Albumin Low, Grade 3000000
Calcium Corrected for Albumin Low, Grade 4000000
Creatinine High, Grade 120141212183
Creatinine High, Grade 2212210
Creatinine High, Grade 3010100
Creatinine High, Grade 4000000
Glomerular Filtration Rate, Estimated Low, Grade 1000021
Glomerular Filtration Rate, Estimated Low, Grade 20000112
Glomerular Filtration Rate, Estimated Low, Grade 3000000
Glomerular Filtration Rate, Estimated Low, Grade 4000000
Glucose High, Grade 115131212113
Glucose High, Grade 21063582
Glucose High, Grade 3221420
Glucose High, Grade 4000000
Glucose Low, Grade 1010110
Glucose Low, Grade 2000000
Glucose Low, Grade 3000000
Glucose Low, Grade 4000000
Lipase High, Grade 1000200
Lipase High, Grade 2001200
Lipase High, Grade 3000200
Lipase High, Grade 4000200
Phosphate Low, Grade 1982700
Phosphate Low, Grade 2253640
Phosphate Low, Grade 3204200
Phosphate Low, Grade 4000000
Potassium High, Grade 1110010
Potassium High, Grade 2000100
Potassium High, Grade 3000000
Potassium High, Grade 4010000
Potassium Low, Grade 1655812
Potassium Low, Grade 2000000
Potassium Low, Grade 3203120
Potassium Low, Grade 4001000
Sodium High, Grade 1022000
Sodium High, Grade 2000000
Sodium High, Grade 3000000
Sodium High, Grade 4000000
Sodium Low, Grade 11174970
Sodium Low, Grade 2000000
Sodium Low, Grade 3113301
Sodium Low, Grade 4000010
Total Bilirubin High, Grade 1324320
Total Bilirubin High, Grade 2001400
Total Bilirubin High, Grade 3000100
Total Bilirubin High, Grade 4000000
Urate High, Grade 1000000
Urate High, Grade 2000000
Urate High, Grade 3574940
Urate High, Grade 4300200
SecondaryComplete Response Rate

Complete response rate is defined as the percentage of patients with CR

Time frame:
Up to 81 months
Reported as:
Number · Percentage of participants
Complete Response Rate
Percentage of participantsPart APart BPart CPart DPart EPart F
Complete Response Rate70 (49.8 to 86.2)64 (40.7 to 82.8)75 (50.9 to 91.3)67 (43.0 to 85.4)30 (14.7 to 49.4)43 (9.9 to 81.6)
SecondaryDuration of Complete Response

Duration of CR per investigator was defined as the time from start of the first documentation of CR to the first documentation of tumor progression or to death due to any cause, whichever came first. For Parts E and F, the assessment was per BICR.

Time frame:
Up to 81 months
Reported as:
Median · Months
Duration of Complete Response
MonthsPart APart BPart CPart DPart EPart F
Duration of Complete Response7.4 (5.1 to NA)NA (14.7 to NA)NA (2.8 to NA)NA (6.6 to NA)NA (7.4 to NA)NA (NA to NA)
SecondaryDuration of Objective Response

Duration of response per investigator was defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression (PD) based on radiographic evidence of progression or to death due to any cause, whichever came first. For Parts E and F, the assessment was per BICR.

Time frame:
Up to 81 months
Reported as:
Median · Months
Duration of Objective Response
MonthsPart APart BPart CPart DPart EPart F
Duration of Objective Response7.6 (5.1 to 67.7)46.0 (8.5 to NA)NA (3.6 to NA)NA (12.7 to NA)7.4 (7.4 to NA)NA (11.3 to NA)
SecondaryProgression-free Survival

Progression-free survival (PFS) per investigator was defined as the time from start of study treatment to first documentation of tumor progression or to death due to any cause, whichever came first. For Parts E and F, the assessment was per BICR.

Time frame:
Up to 83 months
Reported as:
Median · Months
Progression-free Survival
MonthsPart APart BPart CPart DPart EPart F
Progression-free Survival8.6 (6.3 to 40.1)47.2 (10.8 to NA)32.5 (4.0 to NA)NA (9.4 to NA)8.7 (5.1 to NA)10.5 (0.5 to NA)
SecondaryDisease Control Rate

Disease control rate (DCR) per investigator was defined as the percentage of subjects with CR, PR, or SD, per investigator assessment of best clinical response per Cheson 2007. For Parts E and F, the assessment was per BICR.

Time frame:
Up to 81 months
Reported as:
Number · Percentage of participants
Disease Control Rate
Percentage of participantsPart APart BPart CPart DPart EPart F
Disease Control Rate100 (87.2 to 100.0)95 (77.2 to 99.9)85 (62.1 to 96.8)90 (69.6 to 98.8)77 (57.7 to 90.1)57 (18.4 to 90.1)
SecondaryORR According to Lugano Criteria Per BICR (Parts E and F)

Objective response rate (ORR) per investigator was defined as the percentage of subjects with CR or PR through the end of study or prior to the start of new anti-cancer treatment (including stem cell transplant, and excluding consolidative radiotherapy) other than the study treatment.

Time frame:
Up to 31 months
Reported as:
Number · Percentage of participants
ORR According to Lugano Criteria Per BICR (Parts E and F)
Percentage of participantsPart EPart F
ORR According to Lugano Criteria Per BICR (Parts E and F)67 (47.2 to 82.7)43 (9.9 to 81.6)
SecondaryB Symptom Resolution Rate

B symptom resolution rate per investigator was defined as the percentage of subjects with lymphoma-related B symptoms at baseline who achieved resolution of all B symptoms at any time during the treatment period.

Time frame:
Up to 42 weeks
Reported as:
Number · Percentage of participants
B Symptom Resolution Rate
Percentage of participantsPart APart BPart CPart DPart EPart F
B Symptom Resolution Rate100 (47.8 to 100.0)100 (54.1 to 100.0)86 (42.1 to 99.6)67 (22.3 to 95.7)0 (NA to NA)0 (NA to NA)
SecondaryNumber of Participants With Brentuximab Vedotin Antitherapeutic Antibodies (ATA)
Time frame:
Up to 30 months
Reported as:
Count of participants · Participants
Number of Participants With Brentuximab Vedotin Antitherapeutic Antibodies (ATA)
ParticipantsPart APart BPart CPart DPart EPart F
Baseline Negative23201617246
Baseline Negative - Negative post-baseline1412512176
Baseline Negative - Positive post-baseline9811570
Baseline Positive321120
Baseline Positive - Negative post-baseline321120
Baseline Positive: Treatment-boosted post-baseline000000
SecondaryNumber of Participants With Nivolumab Antitherapeutic Antibodies (ATA) (Part D Only)
Time frame:
Up to 30 months
Reported as:
Count of participants · Participants
Number of Participants With Nivolumab Antitherapeutic Antibodies (ATA) (Part D Only)
ParticipantsPart D
Cycle 1 (Pre-dose nivolumab)0
First Positive Cycle (pre-dose) - Cycle 24
First Positive Cycle (pre-dose) - Cycle 81
Any positive post-baseline5
SecondaryOverall Survival (Parts E and F Only)

Overall survival (OS) per investigator was defined as the time from date of enrollment to date of death due to any cause.

Time frame:
Up to 44 months
Reported as:
Median · Months
Overall Survival (Parts E and F Only)
MonthsPart EPart F
Overall Survival (Parts E and F Only)31.8 (14.8 to NA)12.6 (0.5 to NA)

Adverse events

Collected over Non-serious Adverse Events, Serious Adverse Events, and All-Cause Mortality were followed for up to 122 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A13/27 (48.1%)5/27 (18.5%)27/27 (100%)
Part B9/22 (40.9%)4/22 (18.2%)22/22 (100%)
Part C12/20 (60%)13/20 (65%)20/20 (100%)
Part D4/21 (19%)4/21 (19%)21/21 (100%)
Part E10/30 (33.3%)14/30 (46.7%)27/30 (90%)
Part F5/7 (71.4%)4/7 (57.1%)7/7 (100%)
Most frequent serious events
Showing 10 of 72
Most frequent serious events
EventPart APart BPart CPart DPart EPart F
Myocardial infarctionCardiac disorders0/270/220/200/210/301/7
NauseaGastrointestinal disorders0/270/220/203/210/300/7
VomitingGastrointestinal disorders0/270/220/203/210/300/7
COVID-19Infections and infestations0/270/220/200/210/301/7
PneumoniaInfections and infestations0/270/222/200/212/301/7
Septic shockInfections and infestations0/270/221/200/210/301/7
Urinary tract infectionInfections and infestations0/271/222/200/210/301/7
Fibula fractureInjury, poisoning and procedural complications0/270/220/200/210/301/7
Tibia fractureInjury, poisoning and procedural complications0/270/220/200/210/301/7
Tumour lysis syndromeMetabolism and nutrition disorders0/270/220/200/210/301/7
Most frequent other events
Showing 10 of 103
Most frequent other events
EventPart APart BPart CPart DPart EPart F
DiarrhoeaGastrointestinal disorders9/276/2217/209/217/304/7
Peripheral sensory neuropathyNervous system disorders21/2717/228/2010/2114/304/7
FatigueGeneral disorders12/2710/2210/2016/219/301/7
NauseaGastrointestinal disorders12/279/2213/208/2110/303/7
ConstipationGastrointestinal disorders8/2710/227/2010/215/301/7
Decreased appetiteMetabolism and nutrition disorders8/275/229/207/218/301/7
Weight decreasedInvestigations6/275/225/204/214/303/7
PyrexiaGeneral disorders2/274/227/207/212/300/7
DehydrationMetabolism and nutrition disorders3/271/227/201/211/300/7
ChillsGeneral disorders1/272/223/207/212/300/7

Baseline characteristics

The Full Analysis Set includes all participants who received any amount of brentuximab vedotin.

Age, Categorical
Age, Categorical(Participants)Part APart BPart CPart DPart EPart FTotal
<=18 years0000000
Between 18 and 65 years23141112
>=65 years25191917296115
Sex: Female, Male
Sex: Female, Male(Participants)Part APart BPart CPart DPart EPart FTotal
Female13610616253
Male1416101514574
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part APart BPart CPart DPart EPart FTotal
Hispanic or Latino24012211
Not Hispanic or Latino25182020285116
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part APart BPart CPart DPart EPart FTotal
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American1302006
White26192019267117
More than one race0000101
Unknown or Not Reported0000303
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Part APart BPart CPart DPart EPart FTotal
Grade 096445028
Grade 1129121610463
Grade 2574010228
Grade 31000517
Grade 40000000
Grade 50000000
Missing0001001
08

Study locations

54 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • University of South Alabama - Mitchell Cancer Institute
    Mobile, Alabama 36604, United States
  • Alaska Urological Institute
    Anchorage, Alaska 99503, United States
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • Arizona Oncology Associates, PC - HOPE
    Tucson, Arizona 85710, United States
  • Arizona Cancer Center / University of Arizona
    Tucson, Arizona 85724-5024, United States
  • Highlands Oncology Group
    Springdale, Arkansas J. Thaddeus Beck, United States
  • Providence St Joseph Medical Center
    Burbank, California 91505, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Wilshire Oncology Medical Group Inc.
    Pomona, California 91767, United States
  • Rocky Mountain Cancer Centers - Aurora
    Aurora, Colorado 80012, United States
  • Florida Cancer Affiliates
    Trinity, Florida 34655, United States
  • IACT Health
    Columbus, Georgia 31904, United States
  • Georgia Cancer Specialists / Northside Hospital Cancer Institute
    Sandy Springs, Georgia 30341, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Illinois Cancer Specialists / Advocate Lutheran General Hospital
    Niles, Illinois 60714, United States
  • American Oncology Networks LLC
    Bethesda, Maryland 20817, United States
  • Karmanos Cancer Institute / Wayne State University
    Detroit, Michigan 48201, United States
  • Minnesota Oncology Hematology P.A.
    Minneapolis, Minnesota 55404, United States
  • Nebraska Cancer Specialists
    Omaha, Nebraska 68130, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Morristown Medical Center/ Carol G. Simon Cancer Center
    Morristown, New Jersey 07960, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
  • New York Oncology Hematology, P.C.
    Albany, New York 12208, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • James P. Wilmot Cancer Center / University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Oncology Hematology Care
    Cincinnati, Ohio 45242, United States
  • James Cancer Hospital / Ohio State University
    Columbus, Ohio 43210, United States
  • Willamette Valley Cancer Institute and Research Center
    Eugene, Oregon 97401, United States
  • Northwest Cancer Specialists, P.C.
    Tigard, Oregon 97223, United States
  • Prisma Health
    Greenville, South Carolina 29615, United States
  • Arlington Cancer Center
    Arlington, Texas 76012, United States
  • Texas Oncology - Bedford
    Bedford, Texas 76022, United States
  • Texas Oncology - Presbyterian Cancer Center Dallas
    Dallas, Texas 75231, United States
  • Texas Oncology - Denton South
    Denton, Texas Kurkul, United States
  • Texas Oncology - Fort Worth 12th Avenue
    Fort Worth, Texas 76104, United States
  • Houston Methodist Cancer Center
    Houston, Texas 77030, United States
  • MD Anderson Cancer Center / University of Texas
    Houston, Texas 77030, United States
  • Texas Oncology - Longview
    Longview, Texas 75601, United States
  • Texas Oncology - McAllen
    McAllen, Texas 78503, United States
  • Texas Oncology - Seton Williamson
    Round Rock, Texas 78665, United States
  • Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
  • Virginia Commonwealth University Medical Center
    Richmond, Virginia 23298, United States
  • Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care
    Salem, Virginia 24153, United States
  • Shenandoah Oncology P.C.
    Winchester, Virginia 22601, United States
  • Benaroya Research Institute/Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • Wenatchee Valley Medical Center
    Wenatchee, Washington 98821, United States
  • Carbone Cancer Center / University of Wisconsin
    Madison, Wisconsin 53792, United States
  • University of Alberta / Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • London Health Sciences Centre - Victoria Hospital
    London, Ontario N6A 5W9, Canada
  • CIUSSS de L'Est de l'lle de Montreal / installation Hopital Maisonneuve-Rosemont
    Montreal, Quebec H1T 2M4, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Royal Victoria Hospital, McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
09

References and documents

Publications

  • Friedberg JW, Forero-Torres A, Bordoni RE, Cline VJM, Patel Donnelly D, Flynn PJ, Olsen G, Chen R, Fong A, Wang Y, Yasenchak CA. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged >/=60 years with HL. Blood. 2017 Dec 28;130(26):2829-2837. doi: 10.1182/blood-2017-06-787200. Epub 2017 Oct 16. PubMed 29038340 ↗
  • Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, Bordoni RE, Friedberg JW, Sharman JP, Palanca-Wessels MC, Wang Y, Yasenchak CA. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015 Dec 24;126(26):2798-804. doi: 10.1182/blood-2015-06-644336. Epub 2015 Sep 16. PubMed 26377597 ↗
  • Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, Matous JV, Shustov AR, Smith SE, Zain J, O'Meara MM, Fanale MA. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma. 2014 Oct;55(10):2328-34. doi: 10.3109/10428194.2013.876496. Epub 2014 Feb 24. PubMed 24359243 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2012 to primary completion in Apr 2023, 125 months.

Results were first posted in Jun 2024, 1 year 2 months after primary completion.

Of 206 phase 2 interventional studies under Hodgkin Disease, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 111. This study's 125 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2012
First posted
Oct 30, 2012
StartActual
Oct 31, 2012
Primary completionActual
Apr 7, 2023
CompletionActual
Sep 12, 2023
Results first posted
Jun 11, 2024
Last update
Jun 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01716806
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Oct 30, 2012
Start date
Oct 31, 2012
Primary completion
Apr 7, 2023
Completion
Sep 12, 2023
Results posted
Jun 11, 2024
Last update
Jun 11, 2024

Study contacts

Robert Sims, MD
study director · Seagen Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion